View allAll Photos Tagged CancerImmunotherapy,
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
A team of researchers has developed a system that uses ultrasound to remotely activate genetic processes inside CAR-T cells so that they can target and kill cancer cells. This work addresses one of the major challenges of of CAR-based immunotherapy: non-specific targeting of CAR-T cells against nonmalignant tissues. Researchers say this work could ultimately lead to more precise and efficient CAR-T cell therapies that can better target malignant over benign tissues.
Press release: jacobsschool.ucsd.edu/news/news_releases/release.sfe?id=2412
Photos by David Baillot/UC San Diego Jacobs School of Engineering
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
A team of researchers has developed a system that uses ultrasound to remotely activate genetic processes inside CAR-T cells so that they can target and kill cancer cells. This work addresses one of the major challenges of of CAR-based immunotherapy: non-specific targeting of CAR-T cells against nonmalignant tissues. Researchers say this work could ultimately lead to more precise and efficient CAR-T cell therapies that can better target malignant over benign tissues.
Press release: jacobsschool.ucsd.edu/news/news_releases/release.sfe?id=2412
Photos by David Baillot/UC San Diego Jacobs School of Engineering
A team of researchers has developed a system that uses ultrasound to remotely activate genetic processes inside CAR-T cells so that they can target and kill cancer cells. This work addresses one of the major challenges of of CAR-based immunotherapy: non-specific targeting of CAR-T cells against nonmalignant tissues. Researchers say this work could ultimately lead to more precise and efficient CAR-T cell therapies that can better target malignant over benign tissues.
Press release: jacobsschool.ucsd.edu/news/news_releases/release.sfe?id=2412
Photos by David Baillot/UC San Diego Jacobs School of Engineering
A team of researchers has developed a system that uses ultrasound to remotely activate genetic processes inside CAR-T cells so that they can target and kill cancer cells. This work addresses one of the major challenges of of CAR-based immunotherapy: non-specific targeting of CAR-T cells against nonmalignant tissues. Researchers say this work could ultimately lead to more precise and efficient CAR-T cell therapies that can better target malignant over benign tissues.
Press release: jacobsschool.ucsd.edu/news/news_releases/release.sfe?id=2412
Photos by David Baillot/UC San Diego Jacobs School of Engineering
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
A team of researchers has developed a system that uses ultrasound to remotely activate genetic processes inside CAR-T cells so that they can target and kill cancer cells. This work addresses one of the major challenges of of CAR-based immunotherapy: non-specific targeting of CAR-T cells against nonmalignant tissues. Researchers say this work could ultimately lead to more precise and efficient CAR-T cell therapies that can better target malignant over benign tissues.
Press release: jacobsschool.ucsd.edu/news/news_releases/release.sfe?id=2412
Photos by David Baillot/UC San Diego Jacobs School of Engineering
A team of researchers has developed a system that uses ultrasound to remotely activate genetic processes inside CAR-T cells so that they can target and kill cancer cells. This work addresses one of the major challenges of of CAR-based immunotherapy: non-specific targeting of CAR-T cells against nonmalignant tissues. Researchers say this work could ultimately lead to more precise and efficient CAR-T cell therapies that can better target malignant over benign tissues.
Press release: jacobsschool.ucsd.edu/news/news_releases/release.sfe?id=2412
Photos by David Baillot/UC San Diego Jacobs School of Engineering
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Left to right: Charles Duncan, Managing Director, Senior Analyst, Biotechnology, JMP Securities LLC, and James Gulley, Director, Clinical Trials Group, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio
Watch it at: livestream.com/colgateuniversity/Cancer-Immunotherapy-Hop....
Cancer Immunotherapy: Hope or Hype?
Wed, Nov 16 from 9:30 - 11:30pm EST Business
Presented by the Colgate Professional Networks.
This discussion will cover the history, science, and promise of this new paradigm as well as issues of access, affordability, and ethics.
6:30 p.m. | Panel Discussion
8:00 p.m. | Networking Reception
This event is free to attend. In lieu of a registration fee, we ask that you consider a donation of $13 or more to support the Colgate Internship Fund.
Moderated by Geoff Holm | Associate Professor of Biology, Colgate University
Panelists:
David Beier ’70 | Managing Director, Bay City Capital
Wayne Feinstein ’74 | Senior VP, Capital Group Companies Private Client Services and Founder, Gastric Cancer Foundation
Gregg Fine ’94 | Senior Medical Director, Genentech
Terry Fry ’88 | Head, Hematologic Malignancies Section, NIH, National Cancer Institute
Carin Rollins ’94 | Founder/CEO, Hinge Bio